AWM
MYGN icon

Atticus Wealth Management’s Myriad Genetics MYGN Stock Holding History

Atticus Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$5K – 386
2019
Q4 		$5K Buy
+200
New +$5.5K ﹤0.01% 260

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Atticus Wealth Management's MYGN Position: Q1 2020 in Review

Atticus Wealth Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 200 shares — an estimated $5K sold.

Atticus Wealth Management first reported a position in MYGN in Q4 2019 and held it in 1 quarter. The position peaked at $5K in Q4 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Atticus Wealth Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Atticus Wealth Management sold 200 Myriad Genetics shares in Q1 2020, an estimated $5K.
  • Atticus Wealth Management first reported a position in Myriad Genetics in Q4 2019 and held it in 1 quarter.
  • Atticus Wealth Management's Myriad Genetics position peaked at $5K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Atticus Wealth Management's 13F filing for Q1 2020, filed 23 Apr 2020.